Dr. Shargani: In 2008 Revivogen underwent an independent clinical trial on its effectiveness. The results are as follows:

BIOalternatives has developed a unique test to measure the effects of any compound on Testosterone metabolism in living human skin tissue (reconstructed human epidermis) . The living skin tissues are given equal doses of Testosterone which under normal metabolism is converted to DHT and other androgens. The amount of DHT produced by the test tissue is measured for the contorl and all compounds being tested for comparison. Each compound is tested on three separate tissues to assure the tests validity.

The control is allowed to metabolize Testosterone without any interference so it produces DHT at the maximum rate (100%). Topical application of Finastride which is a known inhibitor of 5AR reduced DHT production by 67% compared to control. Topical application of Dutastride which is also a known inhibitor of 5AR was tested at two concentrations and reduced DHT production by 80% compared to control at the lower concentration (the same concentration as Finastride) and 86% compared to control at the higher concentration. Topical application of an equivalent amount of Revivogen Scalp Therapy reduced DHT production by 90% compared to control which is higher than Finastride and Dutastride (both concentrations).Revivogen scalp therapy also reduced the production of other Testosterone metabolites significantly.

Revivogen Scalp Therapy strongly reduced the production of DHT (by 90% compared to control). You can see the actual study data by finding the study on the right sidebar of this page under "Clinical Trials & Related Studies".